Introduction
 75  Vol. 6 | Issue 2 | Jul-Dec 2015 Drug Development and Therapeutics  75  (HPLC), [3, [12] [13] [14] [15] [16] [17] high performance thin liquid chromatography (HPTLC) [18] [19] [20] [21] and layer chromatograph-mass spectrometry (LC-MS). [22] Ambroxol hydrochloride (ABH) chemically, 4-([2-amino-3,5-dibromophenyl]-methyl)-amino] cyclohexanol hydrochloride is a mucolytic expectorant and used to reduce the viscosity of mucous secretions [23] ( Budavari 1996) . Methods available for the determination of ABHX alone or in combination with other drugs include ultraviolet (UV) spectroscopy, [24, 25] capillary electrophoresis, [26] HPLC, [27] [28] [29] [30] [31] [32] gas chromatography, [33, 34] and LC-MS. [35] There are very less analytical methods reported so far for this combination, and they are based on HPLC. [21, 36] To the best of our knowledge, there is no reported method available for the analysis of this combination by derivative spectroscopy. So an urgent need was felt to develop a UV derivative spectroscopic method, which reduces the cost of analysis on comparing with HPLC or HPTLC method.
Materials and Methods

Instruments and chemicals
A double beam UV-visible spectrophotometer (Shimadzu, 1800) having UV-probe software was used for the analysis. Matched and calibrated quarts cuvettes were used as sample cell. The samples of CEF and ambroxol HCl (ABH) were procured from Dr. Reddy's laboratory, India. The tablets were purchased from local market.
Analytical method development and validation
Different solvents such as methanol, water, phosphate buffer, acetate buffer etc., were used as solvents and either zero crossing points (ZCPs) were not available for either drug or for both drugs. When the solvent was shifted to 0.1N urea, ZCPs were available for both the drugs and hence selected as the solvent. Moreover, it is more preferable as it yields an economical and ecofriendly method by avoiding the use of any organic solvents at any stage in the analysis. Standard solutions of CEF (10 µg/ml) and ABH (10 µg/ml) prepared in 0.1N urea were scanned in the spectrum mode between 200 and 400 nm so as to obtain the respective zero-order spectra. It was converted into first derivative spectra selecting delta λ =4 nm and scaling factor = 1. The overlapped spectra of CEF and ABH showed the presence of the ZCP for both the drugs. That is, ZCP of ABH at which CEF showed the derivative absorbance and vice versa for CEF were noted.
Preparation of stock solution and standard solution
Ten mg of each standard drug were weighed and dissolved separately in 0.1N urea to obtain stock solution (1000 µg/ml) of each drug. These solutions were diluted suitably with 0.1N urea to obtain the standard solutions of CEF and ABH.
Method validation
The method was validated for accuracy, precision, linearity, LOD, and LOQ by the following procedures.
Linearity
The stock solution of CEF (50 µg/ml) and ABH (50 µg/ml) were prepared in 0.1N urea. CEF solutions of various concentrations (5-35 µg/ml) were prepared by diluting appropriate volumes with 0.1N urea. In a similar manner, stock solution of ABH also diluted to prepare various concentrations (3-10.5 µg/ml).The first derivative spectra were recorded using the prepared solutions against 0.1N urea as blank.
Accuracy
The accuracy of the method was determined by calculating recoveries of CEF and ABH by standard addition method. Tablet powder equivalent to 10 mg of CEF was taken in three different volumetric flask and 80%, 100% and 120% of pure cefixime bulk drug was added respectively and diluted with 0.1N urea. Similarly, tablet powder equivalent to 3 mg of ABH was transferred into another three different 10 ml volumetric flasks and to it 80%, 100% and 120% of pure ABH bulk drug was added respectively and diluted with 0.1N urea. The amounts of CEF and ABH were estimated by measuring derivative response at the selected wavelength (306 nm for cefixime and 253 nm for ABH) and the concentrations were calculated from the computed regression equation resulting from the linearity studies. The recovery was performed in triplicate at each specified concentration level.
Precision
The intra-day precision of the proposed first derivative spectrophotometric method was determined by estimating the corresponding response 3 times on the same day for three different concentrations of CEF (10, 20, 30 µg/ml) and ABH (3, 6, 9 µg/ml). The inter-day precision was determined by estimating the corresponding response 3 times on 3 different days for the same concentrations of CEF and ABH.
Limit of detection and limit of quantitation
The limit of detection (LOD) and limit of quantitation (LOQ) were determined on samples containing very low concentrations of the analyte. LOD and LOQ were estimated at a signal to noise ratio of 3:1 and prepared from tablet powder so as to get a final solution containing 30 µg/ml CEF and 10 µg/ml ABH. The amount of CEF and ABH was determined by substituting derivative responses into the equation of the straight line representing the calibration curves for CEF and ABH.
Results and Discussion
Selection of zero crossing point
The first derivative spectrum of CEF has zero absorbance at 253 nm, where ABH gives the significant derivative response, while the first derivative spectrum of ABH has zero absorbance at 306 nm, where cefixime gives the significant derivative response. Therefore, 253 nm and 306 nm were selected for estimation of ABH and CEF, respectively as shown in Figure 1 .
Calibration plot for cefixime trihydrate and ambroxol HCl
Cefixime trihydrate and ABH were showing a linear relationship between concentration (µg/ml) and derivative absorbance. CEF and ABH were linear in the range of 5-35 µg/ml and 3-10.5 µg/ml respectively. From the linear regression analysis, correlation coefficient value (r 2 ) for CEF and ABH was 0.9999 and 0.9999 respectively, which indicated the linearity of the method. From Figure 2 , it was observed that with the increase in CEF concentration, the derivative response at 306 nm was increased. Similarly, the derivative response for ABH at 253 nm was increased with the increase in its concentration. The regression equation for CEF and ABH is shown in the linearity data given in Table 1 .
The accuracy was determined by standard addition method. Three different levels (80%, 100% and 120%) of standards were spiked to commercial tablets in triplicate. The mean of percentage recoveries and % relative standard deviation (RSD) values were calculated and reported in Table 2 . The % recoveries of CEF and ABH were found to be in the range of 99.05-101 and 99.6-100.63, respectively which are satisfactory.
Precision
The repeatability (intra-day precision) of the method was determined by intra-day (n = 3) analysis of three standard solutions of CEF and ABH at the concentration of 10, 20 and 30 µg/ml and 3, 6 and 9 µg/ml respectively. The % RSD of repeatability was <2.0 for both the drugs. Intermediate precision was determined by the inter-day (n = 3) analysis of three standard solutions of CEF and ABH at the Drug Development and Therapeutics  77  concentration of 10, 20 and 30 µg/ml and 3, 6 and 9 µg/ml respectively and reported in Table 3 . The % RSD for inter-day analysis was <2.0 for both the drugs. These statistical data were indicative of good precision.
Limit of detection and limit of quantitation
Limit of detection and LOQ of CEF was found to be 0.187 µg/ml and 0.625 µg/ml respectively. For ABH, LOD was found to be 0.0937 µg/ml and LOQ was found to be 0.312 µg/ml.
Analysis of commercial tablets (assay)
The accuracy of proposed method was evaluated by the assay of commercially available tablets (Ceftas-AL) containing CEF (100 mg) and ABH (30 mg). The results obtained for CEF and ABH were compared with the corresponding labeled amounts and reported in Table 4 . The amount of CEF and ABH found in formulation-I (Ceftas-AL) was 100.373 mg and 30.89 mg. The % RSD for assay results of the formulation (Ceftas-AL) was <2, which indicated the accuracy of the proposed method.
Conclusion
The main objective of the present work was to develop an economical and ecofriendly analytical method for the simultaneous analysis of CEF and ABH in the tablet dosage form, IPQC samples or dissolution samples. The validation study results indicated that the presence of excipients did not interfere with the analysis and hence the method can be employed for bulk drugs as well as formulations. The proposed method has some advantages as neither it requires any sophisticated instruments like HPLC or HPTLC nor costly reagents or solvents. Moreover, the solvent selected for the entire steps was urea which is a nature friendly chemical. 
